Le Lézard
Classified in: Health
Subject: SVY

CRM Devices Market Size Worth $32.4 Billion By 2025 | CAGR: 7.8%: Grand View Research, Inc.


SAN FRANCISCO, February 19, 2018 /PRNewswire/ --

The global cardiac rhythm management (CRM) devices market size is anticipated to reach USD 32.4 billion by 2025, according to a new report by Grand View Research, Inc., registering a 7.8% CAGR during the forecast period. Increase in demand for CRM devices can be attributed to supportive legislative policies by governments in developed and developing countries. Rising incidence of cardiovascular diseases (CVDs), supportive reimbursement scenario, and major advancements in technology are also anticipated to be key factors governing market growth.

     (Logo: http://photos.prnewswire.com/prnh/20160524/371361LOGO )

CRM devices serve as a permanent treatment option for patients suffering from arrhythmias. Innovation in Cardiac Resynchronization Therapy (CRT) devices is expected to drive this market. Additionally, there is an increase in the application of implantable cardioverter-defibrillators (ICDs) as they are now integrated with pacemakers, thus increasing the product's life. Increase in demand for external defibrillators with growing in awareness and rising disease burden of sudden cardiac arrest (SCA) has also been observed. There is an expansion in the market for external defibrillators as governments in developed economies have been working on making countries more cardio-friendly.

According to statistics published by the Sudden Cardiac Arrest Foundation, about 6.0 million people within the U.S. region suffer from cardiac disorders, of which 0.8 million are affected by atrioventricular blockage, leading to cardiac failure. Such an alarming number leads to an increased cost of about USD 20-56 billion annually. CRM devices are being predominantly used to prevent surgical costs and readmission rates in hospitals, thereby propelling market growth.

Browse full research report with TOC on "Cardiac Rhythm Management (CRM) Devices Market Share, Size & Trends Analysis Report By Product (Pacemaker, Defibrillator, Cardiac Resynchronization Therapy), And Segment Forecasts, 2014 - 2025" at: https://www.grandviewresearch.com/industry-analysis/cardiac-rhythm-management-devices-industry

Further Key Findings From the Report Suggest: 

Browse related reports by Grand View Research: 

Grand View Research has segmented the global CRM devices market on the basis of product and region: 

Read Our Blog By Grand View Research: https://www.grandviewresearch.com/blogs/healthcare

About Grand View Research 

Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, we offer market intelligence studies ensuring relevant and fact-based research across a range of industries, from technology to chemicals, materials and healthcare.

Contact:
Sherry James
Corporate Sales Specialist, USA
Grand View Research, Inc
Phone: +1-415-349-0058
Toll Free: 1-888-202-9519
Email: [email protected]

Web: https://www.grandviewresearch.com


These press releases may also interest you

at 22:03
The report titled "Health & Wellness Food Market by Type (Fresh & Natural, Functional Foods & Beverages, Heat & Eat), Nature (Genetically Modified Organism Food, Non-Genetically Modified Organism Food), Fat Content, Category, Free From Category,...

at 21:27
Hanmi Pharmaceutical (KOSPI: 128940, CEO: Jae-Hyun Park), a leading biopharma company in Korea that focuses on research areas such as oncology, obesity/metabolism, and rare diseases, announced it has entered into a Clinical Trial Collaboration and...

at 19:30
Astellas Pharma Inc....

at 19:15
Denver nonprofit Justice Necessary unveils data from its latest study on teen period poverty in Colorado, shedding light on a deeply concerning issue. The findings of this study underscore the urgent need for action to address the need for teens to...

at 19:05
Xaira Therapeutics launched today on a mission to help re-engineer the way we discover and develop medicines through the end-to-end application of emerging AI technologies. A joint incubation by ARCH Venture Partners and Foresite Labs, Xaira launched...

at 18:00
Curio Digital Therapeutics Inc. announced that the U.S. Food and Drug Administration (FDA) has granted clearance to MamaLift PlusTM. MamaLift Plus is the first prescription digital therapeutic for the treatment of postpartum depression (PPD), a...



News published on and distributed by: